COR Investors Have Opportunity to Join Cencora, Inc. Fraud Investigation with the Schall Law Firm

The Schall Law Firm is investigating Cencora, Inc. for potential securities law violations following the company's Q2 2026 earnings miss and guidance reduction on May 6, 2026. Cencora attributed a $2 billion revenue headwind to manufactured list price reductions, causing its stock to plummet 17.4% on the announcement. The investigation focuses on whether the company issued false or misleading statements or failed to disclose material information to investors.

05/18/2026, 2:53 PM • GlobeNewswire

Cencora Lifts 2026 Sales Outlook Despite Q1 Revenue Miss

Cencora reported Q1 fiscal year revenue of $85.93 billion, slightly missing Wall Street estimates of $86.03 billion, but beat earnings expectations with adjusted EPS of $4.08 versus consensus of $4.03. The company raised its 2026 sales growth guidance from 5%-7% to 7%-9% and increased full-year sales guidance to $343.79-$350.22 billion. However, the stock declined 6.67% following the announcement.

02/04/2026, 11:32 AM • Benzinga

Comparator Drug Sourcing Market to Reach USD 2.72 Billion by 2033, Driven by Rising Global Clinical Trials and Outsourcing Trends – SNS Insider

The global comparator drug sourcing market is projected to grow from USD 1.42 billion in 2025 to USD 2.72 billion by 2033, at a CAGR of 8.47%. Growth is driven by increasing global clinical trials, rising complexity of biologics, and growing outsourcing trends. North America leads with 44.60% market share, while Asia-Pacific is the fastest-growing region at 9.03% CAGR. Central sourcing dominates with 55.60% market share, while contract manufacturing organizations are the fastest-growing application segment.

01/23/2026, 11:00 AM • GlobeNewswire

AOP Health’s Rapiblyk™ Now Accessible via Leading US Healthcare Improvement Companies

AOP Health US announced expanded distribution of Rapiblyk™ (landiolol), an FDA-approved ultra-short-acting beta-blocker for treating rapid heart rates in critical care settings. The drug is now available through four major pharmaceutical wholesalers: Cardinal, Cencora Specialty Distribution, McKesson Corporation, and Morris & Dickson, enhancing accessibility for hospitals and health systems nationwide.

01/12/2026, 9:00 AM • GlobeNewswire

Cencora Strikes $5 Billion OneOncology Deal, Pauses Stock Buyback

Cencora agreed to acquire a majority stake in OneOncology for $5 billion, funded through new debt financing. The transaction is expected to close by the end of fiscal 2026 second quarter and is anticipated to be earnings neutral in the first twelve months.

12/15/2025, 9:09 AM • Benzinga

Iterum Therapeutics Provides Business Update

Iterum Therapeutics reports expanding market access for ORLYNVAH™, securing nearly 25% insurance coverage in the U.S. and signing a Medicare Part D rebate agreement with a top Pharmacy Benefit Manager, with potential coverage starting in Q1 2026.

12/05/2025, 8:00 AM • GlobeNewswire

Cencora Says Famed GLP-1 Class Products Drive Growth, Boosts Profit Outlook

Cencora reported strong Q3 financial results with sales increasing 8.7% to $80.66 billion, driven by growth in healthcare solutions and GLP-1 class product sales. The company raised its full-year adjusted EPS guidance and expects continued revenue growth.

08/06/2025, 1:13 PM • Benzinga

Cell and Gene Therapy Third-Party Logistics Market Forecast and Company Analysis Report 2025-2033 Featuring Cencora, Cardinal Health, McKesson, EVERSANA, Knipper Health, Arvato, DHL, and Kuehne+Nagel

The global cell and gene therapy third-party logistics market is projected to grow from $8.66 billion in 2024 to $20.98 billion by 2033, driven by technological advancements, increasing clinical studies, and personalized medicine demands.

07/28/2025, 6:57 AM • GlobeNewswire